 |
 |
Science at the Edge
Engineering Seminar
October 11th, 2013
11:30 a.m., Room1400 Biomedical and
Physical Sciences
Building
Refreshments served at 11:15 a.m.
Michael Snyder
Department of Genetics
Stanford University School of
Medicine
Personalized
Medicine: Personal Omics
Profiling of Healthy and Disease States
Abstract
Personalized
medicine is
expected to benefit from the combination of genomic
information with the global
monitoring of molecular components and physiological states.
To ascertain
whether this can be achieved, we determined the whole genome
sequence of an
individual at high accuracy and performed an integrated
Personal Omics
Profiling (iPOP) analysis, combining genomic, transcriptomic,
proteomic,
metabolomic, and autoantibodyomic information, over a 38-month
period that
included healthy and two virally infected states. Our iPOP
analysis of blood
components revealed extensive, dynamic and broad changes in
diverse molecular
components and biological pathways across healthy and disease
conditions.
Importantly, genomic information was also used to estimate
medical risks,
including Type 2 Diabetes, whose onset was observed during the
course of our
study. Our study demonstrates that longitudinal personal omics
profiling can
relate genomic information to global functional omics activity
for
physiological and medical interpretation of healthy and
disease states.
Bio
Michael
Snyder is the Stanford Ascherman Professor, Chair of Genetics
and the Director
of the Center of Genomics and Personalized Medicine. He
received his
Ph.D. from the California Institute of Technology and
postdoctoral training at
Stanford University. He is a leader in the field of
functional genomics
and proteomics, and one of the major participants of the
ENCODE project.
His laboratory study was the first to perform a large-scale
functional
genomics project in any organism, and has launched many
technologies in
genomics and proteomics. These including the development of
proteome chips,
high resolution tiling arrays for the entire human genome,
methods for global
mapping of transcription factor binding sites (ChIP-chip now
replaced by
ChIP-seq), paired end sequencing for mapping of structural
variation in
eukaryotes, de novo genome sequencing of genomes using high
throughput
technologies and RNA-Seq. These technologies have been used
for characterizing
genomes, proteomes and regulatory networks. Seminal findings
from the Snyder
laboratory include; the discovery that much more of the human
genome is transcribed
and contains regulatory information than was previously
appreciated, and a high
diversity of transcription factor binding occurs both between
and within
species. He has also combined different state-of–the-art omics
technologies to
perform the first longitudinal detailed integrative personal
omics profile
(iPOP) of person and used this to assess disease risk and
monitor disease
states for personalized medicine. He is a co-founder of
several biotechnology
companies including; Protometrix (now part of Life
Technologies), Affomix (now
part of Illumina), Excelix, and Personalis, and he presently
serves on the
board of a number of companies.
For further
information
please contact Prof. Christina Chan, Department of Chemical
Engineering and
Materials Science at [log in to unmask]
Persons with disabilities have the right
to request and
receive reasonable accommodation. Please call the Department of
Chemical
Engineering and Materials Science at 355-5135 at least one day
prior to the
seminar; requests received after this date will be met when
possible.